SG11201608729RA - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents
Membrane-adherent self-assembled systems for treatment of ocular disordersInfo
- Publication number
- SG11201608729RA SG11201608729RA SG11201608729RA SG11201608729RA SG11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA
- Authority
- SG
- Singapore
- Prior art keywords
- membrane
- treatment
- ocular disorders
- assembled systems
- adherent self
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987012P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/028748 WO2015168523A1 (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608729RA true SG11201608729RA (en) | 2016-11-29 |
Family
ID=54359368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608729RA SG11201608729RA (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9901544B2 (enExample) |
| EP (1) | EP3137481B1 (enExample) |
| JP (1) | JP6452725B2 (enExample) |
| KR (1) | KR101890503B1 (enExample) |
| CN (1) | CN106459137B (enExample) |
| AU (2) | AU2015252908B2 (enExample) |
| CA (1) | CA2946373C (enExample) |
| ES (1) | ES2924768T3 (enExample) |
| MY (1) | MY193694A (enExample) |
| NZ (1) | NZ725028A (enExample) |
| SG (1) | SG11201608729RA (enExample) |
| WO (1) | WO2015168523A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2706535T3 (es) * | 2016-07-07 | 2019-03-29 | Salvat Lab Sa | Composiciones oftálmicas que comprenden aceite de ricino y triglicéridos de cadena media |
| WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| CN110785162B (zh) * | 2017-06-22 | 2023-08-01 | Ys生命科学株式会社 | 用于治疗青光眼的滴眼液组合物 |
| US11129862B2 (en) | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
| US11000530B2 (en) * | 2017-09-01 | 2021-05-11 | Murray And Poole Enterprises Ltd | Methods and compositions for the treatment of ophthalmic conditions |
| JP7056480B2 (ja) * | 2017-09-08 | 2022-04-19 | ライオン株式会社 | 眼科用組成物及び涙液油層安定化剤 |
| CN109316440B (zh) * | 2018-09-29 | 2020-12-29 | 华中科技大学 | 一种温敏性液晶纳米水凝胶及其制备方法与应用 |
| EP4233872B1 (en) * | 2018-10-24 | 2025-07-02 | Ferring B.V. | Mucoadhesive pharmaceutical compositions of corticosteroids |
| GB201818043D0 (en) * | 2018-11-05 | 2018-12-19 | Waterford Institute Of Tech | Artifical Tears |
| JP2023527162A (ja) * | 2020-05-18 | 2023-06-27 | マックス バイオロジー カンパニー リミテッド | 脂質ポリマー組成物及び使用方法 |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| US11382910B2 (en) * | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
| WO2022077060A1 (en) * | 2020-10-13 | 2022-04-21 | University Of South Australia | Antimicrobial compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP4049216B2 (ja) * | 2003-05-09 | 2008-02-20 | ポーラ化成工業株式会社 | 液晶構造を有する製剤 |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20050235740A1 (en) * | 2004-04-27 | 2005-10-27 | Guido Desie | Method to improve the quality of dispersion formulations |
| CN101005828B (zh) * | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
| US20080145430A1 (en) * | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
| CN101137370B (zh) * | 2005-02-09 | 2014-08-13 | 参天制药株式会社 | 用于治疗疾病或病症的液体制剂 |
| US8906392B2 (en) | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| JP2010064995A (ja) * | 2008-09-12 | 2010-03-25 | Nikko Chemical Co Ltd | 外用消炎鎮痛剤組成物 |
| US8703922B2 (en) * | 2009-12-25 | 2014-04-22 | Chemgenesis Incorporated | Low-viscosity liquid crystal compound |
| CN101773670A (zh) * | 2009-12-29 | 2010-07-14 | 中山大学 | 一种液晶药物载体 |
| JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
| US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
| NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP3517541B1 (en) * | 2012-05-08 | 2020-07-15 | Nicox Ophthalmics, Inc. | Polymorphic form of fluticasone propionate |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
-
2015
- 2015-05-01 CA CA2946373A patent/CA2946373C/en active Active
- 2015-05-01 NZ NZ725028A patent/NZ725028A/en unknown
- 2015-05-01 JP JP2016565482A patent/JP6452725B2/ja active Active
- 2015-05-01 EP EP15785661.8A patent/EP3137481B1/en active Active
- 2015-05-01 ES ES15785661T patent/ES2924768T3/es active Active
- 2015-05-01 SG SG11201608729RA patent/SG11201608729RA/en unknown
- 2015-05-01 US US15/308,000 patent/US9901544B2/en active Active
- 2015-05-01 AU AU2015252908A patent/AU2015252908B2/en active Active
- 2015-05-01 CN CN201580019868.9A patent/CN106459137B/zh active Active
- 2015-05-01 KR KR1020167030513A patent/KR101890503B1/ko active Active
- 2015-05-01 MY MYPI2016703941A patent/MY193694A/en unknown
- 2015-05-01 WO PCT/US2015/028748 patent/WO2015168523A1/en not_active Ceased
-
2018
- 2018-02-27 US US15/906,352 patent/US10603273B2/en active Active
- 2018-03-06 AU AU2018201596A patent/AU2018201596B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018201596B2 (en) | 2020-02-06 |
| AU2015252908B2 (en) | 2017-12-07 |
| WO2015168523A1 (en) | 2015-11-05 |
| US20170049697A1 (en) | 2017-02-23 |
| KR20160147784A (ko) | 2016-12-23 |
| MY193694A (en) | 2022-10-25 |
| KR101890503B1 (ko) | 2018-08-21 |
| CN106459137A (zh) | 2017-02-22 |
| JP6452725B2 (ja) | 2019-01-16 |
| JP2017514843A (ja) | 2017-06-08 |
| US9901544B2 (en) | 2018-02-27 |
| CN106459137B (zh) | 2019-04-12 |
| NZ725028A (en) | 2019-01-25 |
| EP3137481A4 (en) | 2017-12-27 |
| CA2946373A1 (en) | 2015-11-05 |
| US10603273B2 (en) | 2020-03-31 |
| AU2018201596A1 (en) | 2018-03-29 |
| US20180185275A1 (en) | 2018-07-05 |
| EP3137481A1 (en) | 2017-03-08 |
| AU2015252908A1 (en) | 2016-10-27 |
| CA2946373C (en) | 2018-07-31 |
| EP3137481B1 (en) | 2022-07-06 |
| ES2924768T3 (es) | 2022-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288712B1 (en) | Methods for treating abnormal movement disorders | |
| SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL247515A0 (en) | Snekribirock for the treatment of leprosy | |
| IL250490A0 (en) | A method for treating depression | |
| EP3191185A4 (en) | Device for targeted treatment of dermastoses | |
| EP3119911A4 (en) | Methods for treating neurological disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| EP3091985A4 (en) | Treatment of migraines | |
| EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
| PL2937084T3 (pl) | Sposób leczenia hipercholesterolemii | |
| SMT202300015T1 (it) | N,n-bis-2-mercaptoetil isoftalammide per il trattamento delle malattie neurodegenerative | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders | |
| GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders | |
| AU2014902194A0 (en) | Treatment of immune disorders | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| EP3177316A4 (en) | Method for preventing or treating ocular disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders |